Syntara Limited · ASX:SNT
Syntara — Shareholder Meeting (November 2026)
17 slides from Syntara's shareholder meeting presentation, Nov 19, 2026

Slide 1: 2026 Annual General Meeting CEO Presentation
rsonal use only 2026 Annual General Meeting CEO Presentation Gary Phillips, CEO 19th November 2026

Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT rsonal use only This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the differ

Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS rsonal use only Australian-founded Backed by Multiple shots on Funded into CY28 with near clinical stage specialist healthcare goal from additional term events to drive value drug developer investors – Phase 2, Phase 1 and over the next 12 months. 44% institutional preclinical

Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 18th November 2026 $0.014 Close rsonal use only 0.04 Market cap A$27.5m Cash balance A$14.1m 0.03 Enterprise value A$13.4m 0.02 0.01 Institutional Ownership 30 Sep 26 0 D&A Income Limited 18% Volume Platinu

Slide 5: Assets with Clinical Proof of Concept
ASSETS WITH CLINICAL PROOF OF CONCEPT A clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease ASSET INDICATION TOTAL ADDRESSABLE MARKET DEVELOPMENT STATUS rsonal use only • Phase 2a clinical proof of concept in MF - complete Haematological Myelofibrosis: ~US$2.8b p.a.

Slide 6: Amsulostat: Lead Asset and a Key Driver of Value
• FDA IND and orphan drug designation in rsonal use only myelofibrosis • First and best in class pan-LOX inhibitor • Long patent life AMSULOSTAT: • Multiple Nature publications LEAD ASSET AND A KEY • Final Phase 2a trial data in combination with DRIVER OF VALUE ruxolitinib presented at ASH 2025 • Cl

Slide 7: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~55k people in 7MM (fibrosis) in bone marrow and abnormal proliferation of (USA, Japan, 5EU); USA ~ 20

Slide 8: Myelofibrosis: Limited treatment options currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat rsonal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, inhibiting the family of lysyl oxidase (enlarged spleen

Slide 9: Amsulostat Shows Competitive Efficacy
AMSULOSTAT SHOWS COMPETITIVE EFFICACY Comparison of open-label Phase 2 studies in suboptimal patient populations Phase 2 Open Label Trial Results in Suboptimal Patient Population Latest Program Drug Status Baseline Characteristics rsonal use only N TSS50 SVR25 SVR35 (median, range) Second P3 naïve M

Slide 10: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / / rsonal use only DATE OF JULY-2026 APRIL-2026 MARCH-2026 DEC-2024 FEB-2024 ANNOUNCEMENT* Drug Name Navtemadlin AJ1-11095 Rovadicitinib Elritercept Pelabresib MDS and MF Myelofibrosis Lead Indication / Myelofibrosis Myelofibrosis

Slide 11: BRIDGE-MF: Study Design
BRIDGE-MF: STUDY DESIGN Study designed to strengthen confidence in both efficacy and disease-modifying relevance Trial Design amsulostat Timeline of Activities rsonal use only Main Cohort A 200 mg BID + • Patients with MF on ruxolitinib for min 3 months Preparation Phase ruxolitinib BID • Current in

Slide 12: SNT-4728: Brief History
SNT-4728: BRIEF HISTORY SNT-4728 FOR NEUROINFLAMMATION Safe and efficacious, small molecule enzyme inhibitor that crosses the rsonal use only blood brain barrier A novel approach • Syntara discovered and wholly • Strong preclinical and clinical owned asset data support the role of SSAO • Drug extens

Slide 13: iRBD and Parkinson's Key Facts
iRBD AND PARKINSON’S Using a sleep disorder to target Parkinson’s. KEY FACTS Early intervention to demonstrate neuroprotection – rather than late treatment when most neurons have already been lost (for example in PD) – is where disease-modifying, rsonal use only • Patients with isolated REM sleep be

Slide 14: Reduction in Inflammation
REDUCTION IN Binding Potential (BPND) P-value INFLAMMATION Putamen Mean at Mean at Mean change (Paired t- test) baseline 12 weeks Statistically significant rsonal use only Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 reduction in brain inflammation observed unilaterally in the Left -0.001209 0.001

Slide 15: Clinical Measures
CLINICAL MEASURES MDS-UPDRS Part III Total Score 10 SNT-4728, n=30 Significant difference between rsonal use only Placebo, n=11 SNT-4728 and placebo in motor p=0.021 signs Mean Change, 95% CI p=0.183 5 MDS-UPDRS • Small decrease over time (even after treatment cessation) in the Part III total score

Slide 16: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY H2 2026 H1 2027 PATIENTS PARTICIPANTS rsonal use only FDA approved Partner development plan engagement & Myelofibrosis and partner trial funding engagement discussions Int

Slide 17: Gary Phillips, Chief Executive Officer
rsonal use only Gary Phillips Chief Executive Officer gary.phillips@syntaratx.com.au http://syntaratx.com.au
Source: ASX announcement, Nov 19, 2026
More decks from Syntara Limited
Shareholder Meeting (November 2026)17 slides · Nov 19, 2026
Canaccord Drug & Device Conference 202620 slides · Oct 13, 2026
Corporate Update (July 2026)12 slides · Jul 28, 2026
Investor Presentation (July 2026)31 slides · Jul 27, 2026
Technical Presentation (July 2026)11 slides · Jul 6, 2026
Investor Presentation (June 2026)20 slides · Jun 1, 2026